WIRED @WIRED
California plans to spend hundreds of millions of dollars to make insulins similar to currently available brand-name versions—known as biosimilars. The effort could drop prices anywhere from 47-95%. Here's how it works: https://t.co/PVClkhbibr 📸: Getty https://t.co/1uD2DVAcdk — PolitiTweet.org